Trial · NCT07144956
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
NCT07144956, Phase 3, Not yet recruiting, Centre Hospitalier St Anne
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage. Trials, record NCT07144956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07144956
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
- NCT number
- NCT07144956
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 630 participants, estimated
- Lead sponsor
- Centre Hospitalier St Anne
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Cilostazol (Pletal®) 100 mg Tablets, Placebo, Nimodipine group
- First posted
- 2025-08-28
- Last updated
- 2025-09-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Modified Rankin Scale (mRS) Score at 6 Months After Aneurysmal Subarachnoid Hemorrhage | At 6 months after aneurysmal subarachnoid hemorrhage | Neurological functional outcome will be measured using the modified Rankin Scale (mRS) at 6 months post-aneurysmal subarachnoid hemorrhage. The mRS is a 7-point ordinal scale ranging from 0 (no symptoms) to 6 (death), assessing the degree of disability or dependence in daily activities. |
| Secondary | Functional Outcome at 6 Months Measured by the Subarachnoid Hemorrhage Outcome Tool (SAHOT) | 6 months | SAHOT total score (range: 0-100; higher scores indicate better functional outcome). |
| Secondary | In-hospital morbidity and mortality | 28 days | Length of stay in Intensive Care Unit (ICU) Length of hospital stay 28-day mortality |
| Secondary | Clinical and radiological events predictive of functional status | 6 months | Delayed cerebral ischemia (DCI): focal neurological deficit or a decrease of at least 2 points in the Glasgow Coma Scale, not occurring immediately after aneurysm occlusion and not attributable to other causes. Cerebral vasospasm: reduction in the calibre of proximal cerebral vessels seen on CT angiography, MR angiography, or catheter angiography (DSA), classified according to severity. Cerebral infarcts: diagnosis by CT or MRI scan within 6 weeks (or latest imaging before death within 6 weeks, or at autopsy), not present on the CT or MRI scan performed between 24 and 48 hours after early aneurysm occlusion and not attributable to other causes. |
| Secondary | Incidence of Cilostazol-Related Major and Minor Adverse Events | 6 months. | Major adverse events: arrhythmia, abnormal bleeding, allergy. Minor adverse events: tachycardia, fever, fainting, nausea, vomiting, stomach pain. Notes: Data will be collected from patient reports, clinical assessments, and medical records to evaluate the safety and tolerability of cilostazol. |
| Secondary | Cognitive Function at 6 Months Measured by the Montreal Cognitive Assessment (MoCA) | 6 months | MoCA total score (range: 0-30; higher scores indicate better cognitive function). |
| Secondary | Return to Work at 6 Months | 6 months | Number of participants who have returned to work (yes/no). |
| Secondary | Activities of Daily Living (ADL) at 6 Months | 6 months | Independence in basic self-care activities (scored as dependent/independent). |
| Secondary | Instrumental Activities of Daily Living (IADL) at 6 Months | 6 months | Independence in instrumental daily activities (scored as dependent/independent). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07144956
GET https://conductscience.org/api/trials/v1/NCT07144956/registered